Review
Published · Updated · 1 min read
MERRF syndrome: variable manifestations and symptomatic multidisciplinary management
What it means for practice
Management of MERRF syndrome should be symptomatic and multidisciplinary, with avoidance of mitochondrial toxins. The review discusses coenzyme Q10 and L-carnitine only as potential supportive therapies.
Summary
Clinical and genetic features
The review addresses MERRF syndrome, a maternally inherited mitochondrial disorder. Its characteristic features are myoclonus, epilepsy, cerebellar ataxia, and ragged-red fibers in muscle biopsies. In addition to these manifestations, the abstract describes sensorineural, cardiac, and ophthalmological abnormalities.
The main genetic variant discussed is m.8344A>G in MT-TK. Phenotypic severity varies according to heteroplasmy. The review therefore covers not only the characteristic neurological features but also the associated non-neurological manifestations of the disorder.
Management approaches
Treatment is described as symptomatic, involving multidisciplinary care. Coenzyme Q10 and L-carnitine are mentioned as potential supportive therapies. The importance of avoiding mitochondrial toxins is also emphasized. Innovative therapeutic approaches under investigation are mentioned as well.
Limits of the available information
The abstract provides no quantitative treatment outcomes, doses, or specific regimens for supportive therapies. Their mention is not accompanied by an assessment of the magnitude of clinical benefit or comparative efficacy.
Source
-
Syndrome de MERRF : épilepsie myoclonique avec fibres rouges déchiquetées.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
